Crossmark

RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study

Crossref DOI link: https://doi.org/10.1186/s12885-025-14154-4

Published Online: 2025-04-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Daining

Cao, Manming

Zhang, Yijun

Bi, Liangkuan

Chen, Meiting

Ni, Mengqian

Zheng, Qiufan

Yao, Kai

Liu, Zhuowei

Yang, Xia

Shi, Yanxia

Wu, Zhiming

An, Xin
License Information

Text and Data Mining valid from 2025-04-30

Version of Record valid from 2025-04-30
More Information

Article History

Received: 5 February 2025

Accepted: 14 April 2025

First Online: 30 April 2025

Declarations

:

: This study involving human participants were reviewed and approved by Th Sun Yat-sen University Cancer Center (file number: No. B2024-448). As this study was retrospective, the Ethics Committee of the Sun Yat-sen University Cancer Center agreed to waive the informed consent of patients.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below